Update on RNAi Technology Published by Genetic Engineering News (GEN).

NEW ROCHELLE, N.Y. -- Genetic Engineering News (GEN) has published today a special supplement on RNAi, the revolutionary gene silencing technology that is having an enormous impact on biotechnology product development. Bioindustry analysts predict that RNAi will be a $1 billion market within five years. RNAi is the first supplement in a new series entitled GEN UPDATES in Biotechnology.

"RNAi technology is already being used in gene function analysis, systems biology, high content cellular studies, pathway analysis, and target validation," says John Sterling, Editor-in-Chief of GEN. "Researchers are discussing and investigating RNAi as a way to one day treat cancer, neurodegenerative diseases, AIDS, hepatitis C, and age-related macular degeneration."

The RNAi UPDATE (www.genengnews.com/rnai) articles include "Are siRNAs Specific Enough to Become Therapeutics; Interfering with RNA: Ready for Prime Time; Design Rules for Dicer-Substrate RNAi; Inducible H1 Promoter-Driven Lentiviral siRNA Expression by Stuffer Reporter Deletion; Gel-Based Application of siRNA to Human Epithelial Cancer Cells Induces RNAi-Dependent Apoptosis; and The Nonviral Episomal Replicating Vector pEPI-1 Allows Long-Term Inhibition of bcr-abl Expression by shRNA".

"Our UPDATES in Biotechnology series of supplements add significantly to the expanding knowledge base of critical life science news and information provided by GEN (www.genengnews.com) and peer reviewed journals published by Mary Ann Liebert, Inc. (www.liebertpub.com)," notes Sterling. "We have a 25-year history as the leading publisher in the field of biotechnology, and our knowledge of the technologies and their market values is unparalleled."

Genetic Engineering News is published 21 times a year by Mary Ann Liebert, Inc. For a copy of the issue, which includes the RNAi UPDATE, please call 914-740-2122, or email: [e-mail]